Loading...

Cunningham Hit Ground Running When It Came To Tamping Down on Drug Prices

December 4, 2019 by Dan McCue
Cunningham Hit Ground Running When It Came To Tamping Down on Drug Prices

WASHINGTON – In the Lowcountry of South Carolina, Rep. Joe Cunningham’s race for Congress quickly became the stuff of local legend.

Here was a first-time candidate, a Democrat running in a staunchly Republican district, who defeated a well-financed GOP opponent, to become the first Democratic representative from South Carolina’s 1st Congressional District since 1981.

But the ever-energetic congressman didn’t stop there. Almost as soon as he arrived in Washington, at a time when many newcomers were still losing their way in the Capitol’s winding hallways, he was looking to fulfill some important campaign promises.

The first was filing a bill to ban offshore oil and gas exploration off the South Carolina coast. Soon thereafter, he actively joined efforts in the House to lower the cost of prescription drugs.

“One of my earliest constituent meetings was with Lowcountry parents who struggle to afford life-saving insulin for their children,” Cunningham recently said of the urgency he felt.

“In the last five years, the cost of one of the most common brands of insulin has increased from $2,907 a year to more than $4,700 a year. Meetings like these reaffirm to me how urgent this issue is,” he said.

In May, he voted in favor of H.R. 986, a bipartisan bill designed to strengthen protections for people with pre-existing conditions, an effort to buttress the Affordable Care Act against administration efforts to weaken it.

He followed up that vote, by introducing the CLAY Act, which would lower the cost of prescription drugs for beneficiaries who receive the low-income subsidy (LIS) in Medicare Part D.

More recently, Cunningham joined with fellow members of the Blue Dog Coalition of moderate House Democrats to endorse a series of prescription drug pricing bills that they believe, if taken up individually, could pass a Democratic-led House and a Republican-led Senate.

They include the CREATES Act and BLOCKING Act, bills aimed at helping generic drug makers bring their products to market more quickly while also lifting barriers to competition.

Cunningham told The Well News that when it comes to the issue of drug pricing, he expects meaningful results to be achieved, even against the headwinds of the ongoing impeachment proceedings and the impending 2020 political campaigns.

“Of course I do,” he said.

“My top priority in Congress is to serve the people of the Lowcountry and I know that my colleagues on both sides of the aisle feel the same way about their districts and their constituents,” Cunningham said.

“Lowering the cost of prescription drugs isn’t a Democratic or Republican issue – it’s an American one,” he added.

“Frankly, this issue is far beyond politics, this is about quality of life,” he said. “Nearly 3-in-10 South Carolinians have reported that they’ve had to stop taking medication as prescribed because of cost in the last year,” he said. “We need to get this legislation signed into law as soon as possible for them – and for folks across the nation.”

In The News

Health

Voting

Prescription Drugs

April 27, 2022
by Tom Ramstack
Lawmakers Say Consulting Firm Marketing Contributed to Half-Million Opioid Deaths

WASHINGTON — A congressional panel cast suspicions on a global business consulting firm Wednesday as a potential villain in the... Read More

WASHINGTON — A congressional panel cast suspicions on a global business consulting firm Wednesday as a potential villain in the opioid epidemic that has killed more than a half-million Americans. A McKinsey & Co. official admitted to earning at least $86 million for helping pharmaceutical companies... Read More

April 19, 2022
by Dan McCue
Supreme Court Seeks Solicitor General Input on Biologic Drug Patents

WASHINGTON — The U.S. Supreme Court on Monday asked Solicitor General Elizabeth Prelogar to weigh in on a drug patent... Read More

WASHINGTON — The U.S. Supreme Court on Monday asked Solicitor General Elizabeth Prelogar to weigh in on a drug patent case the outcome of which could ultimately be worth billions of dollars. The case, Amgen v. Sanofi, emanates from the U.S. District Court for the Federal... Read More

House Passes $35-a-Month Insulin Cap as Dems Seek Wider Bill

WASHINGTON (AP) — The House has passed a bill capping the monthly cost of insulin at $35 for insured patients,... Read More

WASHINGTON (AP) — The House has passed a bill capping the monthly cost of insulin at $35 for insured patients, part of an election-year push by Democrats for price curbs on prescription drugs at a time of rising inflation. Experts say the legislation, which passed 232-193... Read More

March 30, 2022
by Dan McCue
House to Vote on Insulin Price Reduction Bill Thursday

WASHINGTON — The House on Thursday is expected to vote to cap the out-of-pocket cost of insulin for consumers at... Read More

WASHINGTON — The House on Thursday is expected to vote to cap the out-of-pocket cost of insulin for consumers at $35 per month. If also passed by the Senate, which is expected to vote the measure up by Easter, the long-awaited reform will go into effect... Read More

March 19, 2022
by TWN
Congressional Panel Takes Deep Dive Into Future of FDA’s Accelerated Approvals

WASHINGTON — The House Energy and Commerce Subcommittee on Health panel Thursday spent the majority of their time considering the... Read More

WASHINGTON — The House Energy and Commerce Subcommittee on Health panel Thursday spent the majority of their time considering the future of the Food and Drug Administration's so-called Accelerated Approval Program. A number of the 20 different health care-related bills discussed by the subcommittee figure in... Read More

March 19, 2022
by TWN
CMS Decision to Limit Coverage of Alzheimer’s Treatment Takes Center Stage

WASHINGTON — A House panel scheduled to kick the tires on roughly 20 different health care-related bills on Thursday spent... Read More

WASHINGTON — A House panel scheduled to kick the tires on roughly 20 different health care-related bills on Thursday spent time considering the Food and Drug Administration’s decision to grant accelerated approval to the first disease-modifying treatment for Alzheimer’s disease and the Centers for Medicare and... Read More

News From The Well